Experiments conducted on worms, zebrafish, mice and, finally, on human subjects in a limited clinical trial conclude that pimozide may be effective in treating what’s known as “Lou Gehrig’s disease.”
Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
An article published today in JCI Insight concludes that pimozide was found to be safe and over the short term, preliminary data shows that it could stabilize the progression of ALS. This neurodegenerative disease normally leads to a progressive paralysis of the skeletal muscles and, on average, three years after the onset of symptoms, to death.
“This medication alleviates the symptoms of ALS in animal models,” said Alex Parker, a CRCHUM researcher and professor at Université de Montréal. “Riluzole and edaravone, the drugs currently used, have modest effects. Other studies must be conducted to confirm our results, but we believe that we’ve found a medication that may prove to be more effective in improving patients’ quality of life.”
FROM WORM TO MAN
The story behind the discovery began six years ago with a little millimeter-long nematode worm called C. elegans. In his laboratory, Parker genetically modified the worms so that they would exhibit aspects of the human form of ALS. Simultaneously, his colleague Pierre Drapeau did the same thing to another animal, the zebrafish, a tiny tropical fish only 5 centimetres long.
The two scientists obtained funding from the U.S. Department of Defense to test medications on these worms and fish born with ALS. “We sifted through a library of 3,850 molecules approved for the treatment of other diseases, and found a class of antipsychotic drugs that stabilize mobility in worms and fish,” said Drapeau, a CRCHUM researcher, professor at Université de Montréal and principal investigator on the study. “Pimozide works especially well in preventing paralysis in fish by preserving the neuromuscular junction.”
Subsequently, Université de Montréal Professor Richard Robitaille performed electrophysiological tests on mice in his laboratory and reached the same conclusion. Thus, pimozide was shown to maintain neuromuscular function in three different animal models: worms, fish and mice.
At the annual ALS Canada Research Forum in 2012, the researchers met Dr. Lawrence Korngut, an Associate Professor at the CSM, member of the Hotchkiss Brain Institute (HBI) and Director of the Calgary ALS/Motor Neuron Disease Clinic. “Pimozide is a drug that has been well-known for 50 years,” the neurologist said. “It was approved for treating certain types of psychiatric conditions, like schizophrenia, and costs only 9 cents per pill. Other recent studies have shown genetic links between schizophrenia and ALS. The next logical step was to test it on human volunteers with ALS.”
In 2015, the first preclinical trial for ALS was launched in Canada with a small group of 25 patients who had ALS. Funding was provided by the Quirk family of Calgary, by the HBI, and the Clinical Research Unit at UCalgary.
“We found the highest dose most likely to be tolerated in individuals with ALS – a lower dose than that used in other conditions – and we have preliminary proof showing that pimozide may be useful,” said Korngut.
The initial clinical trial was modest in scope. But after only six weeks, the researchers had a first indication of the drug’s efficacy. Loss of control of the thenar muscles, located in the palm of the hand between thumb and index finger, is usually one of the first signs of ALS. For patients who took pimozide, this function remained stable. This observation is tempered by the very limited size and length of the clinical trial.
“For us, this is an indication that we found the right therapeutic target,” said Drapeau. “Pimozide acts directly on the neuromuscular junction, as shown in our animal models. We don’t yet know whether pimozide has a curative effect, or whether it only preserves normal neuromuscular function to at least stabilize the disease. This is also the first time that a potential drug for human patients was discovered based on basic research on small organisms such as worms and fish.”
Now comes the next step: a phase II clinical trial on 100 volunteers, funded by the “The Ice Bucket Challenge” through a partnership between ALS Canada and Brain Canada to begin in the next few weeks. Headed by Korngut in Calgary and conducted in nine hospital centres across Canada, the study aims to confirm that pimozide is safe and to measure, over a six-month period, its effect on the progression of the disease and its symptoms and on patients’ quality of life.
Daniel Rompré, 47, father of two teenage girls, hopes to participate in the new study. He was diagnosed with ALS in March 2016. The muscles of his upper body are getting weaker, he is beginning to have trouble speaking, and he can no longer use his left arm. “It is hard to maintain a positive outlook,” Rompré said. “You ask yourself: ‘Why me?’ But at least it’s encouraging to see that research is advancing. There has been more progress in the last five years than in 100 years of research on the disease.”
It is too soon to draw firm conclusions about the safety and efficacy of pimozide. “At this stage, people with ALS should not use this medication,” Korngut emphasized. “We must first confirm that it is really useful and safe in the longer term. It is also important to be aware that pimozide is associated with significant side effects. Therefore, it should only be prescribed in the context of a research study.”
The Latest on: Lou Gehrig’s disease
- Can NSAIDs prevent Alzheimer's disease? on April 17, 2019 at 2:32 pm
It will study a variation of a drug currently used for patients with ALS or Lou Gehrig's disease and how it might help Alzheimer's patients. Dr. Finney said, "We need to look in new places, new ... […]
- Collaborative Medicinal Development LLC wins AU$1 million grant award from FightMND on April 17, 2019 at 9:40 am
CMD's goal is to advance a disease modifying therapy for ALS and to have CuATSM approved by the FDA. "FightMND is dedicated to finding an effective treatment or cure for MND, also referred to as ALS ... […]
- What Is Parkinson's Disease, and How Is It Treated? on April 17, 2019 at 9:33 am
It’s a disease that doesn’t discriminate. Actor Michael J. Fox was diagnosed at age 29. Boxing champion Muhammad Ali and country legend Johnny Cash had it, too. More people have PD than multiple ... […]
- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference on April 16, 2019 at 11:13 am
development and commercialization of protein kinase inhibitors (PKIs), presented new preclinical data for masitinib in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, at the ... […]
- Pretty Lou Charity Concert Featuring Fat Joe, Remy Ma & More To Stream On Tidal on April 16, 2019 at 7:09 am
The philanthropic showcase is aiding in the fight against Leukemia and Lou Gehrig's disease. Share Copy Link Tweet (AllHipHop News) The third annual Pretty Lou Birthday Charity Concert will ... […]
- HudsonAlpha and Crestwood collaborate to make advances in ALS on April 14, 2019 at 3:53 pm
HUNTSVILLE, AL (WAFF) - We’ve all seen the devastating impact of ALS, also known as Lou Gehrig’s disease. It weakens muscles and impacts physical function. Now, scientists at the HudsonAlpha Institute ... […]
- An ALS patient's dilemma: End his own life, or die slowly of the disease? on April 13, 2019 at 2:47 am
PARKER, Colo. — In early February, as Lou Gehrig’s disease left him fighting to breathe, George Gallegos had a decision to make: Was he ready to die? Gallegos, 68, a retired psychologist, sat in an ... […]
- Beloved Channel 3 anchor Bill Markham battles ALS on April 12, 2019 at 5:51 pm
Bill Markham is dealing with ALS, known to many as Lou Gehrig's Disease, and he and his family wanted Cindy Sexton to share the news of their journey with you. We need to share a very personal story ... […]
- Jaci’s Story: Two parents’ journey to help their daughter beat ALS on April 11, 2019 at 7:45 pm
Jaci recently was diagnosed with a rare and aggressive form of ALS, or Lou Gehrig’s Disease. Eight years ago, the disease took the life of her twin sister, Alex. It’s a deja vu of the worst ... […]
- Alumni Lead the Fight Against ALS in Upstate New York on April 11, 2019 at 11:24 am
One hundred cases of ALS, also known as Lou Gehrig’s disease, are diagnosed in Upstate New York annually. For those identified with ALS, as well as their families and caregivers, the Upstate New York ... […]
via Google News and Bing News